Strut Health NAD+ Review: The Page Describes the Wrong Molecule

Strut Health does something on its NAD+ page that almost nobody on our board does: it prints a milligram beside the price. A 500 mg subcutaneous injection, from $149 a month. Most of this industry publishes a figure with no strength attached, which makes the figure impossible to compare against anything.

And then, one scroll further down the same page, it explains what NAD+ is: "a peptide that signals your own pituitary gland."

It is not. NAD+ is a coenzyme — a small nucleotide every cell uses in the reactions that turn food into usable energy. It is not a peptide, it does not signal the pituitary, and nothing about that sentence is a near-miss. It is the description of sermorelin, a different product Strut sells on a different page, pasted onto this one.

On a general telehealth site that is a copy-paste error. On a site about what people are told to expect from a molecule, it is the whole problem, because the sentence a company writes to explain what it is selling you is the only account of the product most buyers will ever read.

What Strut is, and what it charges

Strut Health, LLC operates out of 701 Commerce Street in Dallas, Texas, with Simal Patel, MD named as chief executive — an individual named at all, which is rarer in this category than it should be. A licensed clinician reviews an online intake behind a Persona identity check, and the medication is compounded and shipped.

The catalogue around NAD+ is unusually shaped. Sermorelin ships both as an injection and as an oral lozenge, which very few operators offer. Strut also sells its own capsule supplements, PeptideVite and StrutVite. What it does not sell is a second NAD+ route, glutathione, methylene blue, or a standalone B-12 injection — so if you came for a nasal spray, this is not the shop.

The auto-refill structure behind the headline

Every headline figure Strut advertises is an auto-refill rate — the price if you leave a recurring subscription running. That is a normal enough arrangement, and it is not hidden. The problem is what sits on the other side of it: Strut publishes the one-off, non-auto-refill price for almost nothing.

For NAD+, the one-off price is not published at all. We know the size the gap can reach because Strut does publish it in two places on its weight-loss line, and it is large: injectable tirzepatide is $199 on auto-refill and $325 as a one-off, a 63% premium for the same 30-day supply, under a badge advertising a 14% saving that does not reconcile with either number.

We are not going to infer a NAD+ one-off price from that. A number a company has not published is not a number, and back-solving one would be exactly the fabrication this board exists to catch. What a reader should take is the shape: $149 is the subscribed price, the unsubscribed price is unstated, and on the one product line where Strut shows both, the difference is much bigger than the badge implies.

The other structural note is that Strut's newer `/peptides`, `/testosterone` and `/weight-loss` templates ship with no prices on them at all — so which URL you land on decides whether you see a figure.

The FDA warning letter

There is a live FDA warning letter against this company and it is not closed out.

It is addressed to "Strut Health, LLC dba Strut" and was issued in February 2026 by the Center for Drug Evaluation and Research. In the FDA's public warning-letter index, the close-out column for it is empty, which means no close-out letter has been issued. The letter's own recipient block names Strut's chief executive and its Dallas address and states that FDA reviewed struthealth.com — the same site this review is about, so this is the company and not a name collision.

We are not going to restate what it alleges. That is the FDA's document to characterise, and paraphrasing an enforcement action on a page that earns a commission from the company would turn a public record into an accusation of ours. The entity string above is the search term: type it into the FDA's warning-letter database and read the letter itself.

One thing we will state, because it is an observation about the website rather than a characterisation of the letter: Strut makes no mention of it anywhere on its own site.

A letter does not remove a provider from our board and never has. Other companies we rank carry one and stay ranked with the same notice printed on every surface that sells them, paid and unpaid alike. What it does is create an obligation on us to say so before you press anything.

Where Strut is genuinely better than its neighbours

The state list reconciles. Strut's own checkout returns 51 jurisdictions — 49 states plus Washington DC and Puerto Rico, with Arkansas the only exclusion — and the FAQ says the same thing. That sounds like a low bar until you have read the rest of this field, where "all 50 states" badges sit on pages whose terms disclaim state availability, and where at least one company points its state list at a page that does not exist.

The seal resolves. Strut's LegitScript certification ID returns a live record from LegitScript's own image server, checked against an invented control in the same pass. That is a real check rather than a badge.

The dose is published. 500 mg, stated, beside the price. Compare that with the several providers we rank whose every figure reads "starting at" with no strength anywhere — which makes a per-milligram comparison impossible and is one of the recurring problems with how NAD+ dosing is presented.

Where it is worse

No compounding pharmacy is named. "U.S. compounding pharmacies" is the whole disclosure. Several companies we rank name theirs — one names seven — and naming one is what makes it checkable.

The refund policy was last modified in September 2021. Five years is a long time for the document that governs what happens when something goes wrong. Its substance: no refunds once medication leaves the pharmacy, and subscriptions cancellable with 48 hours' notice.

"Medical Necessity Required" appears on every GLP-1 with no published criteria for what would satisfy it.

And the NAD+ explanation is wrong. We have come back to it deliberately, because of everything on this page it is the thing most likely to change what a reader believes they are buying. A company that has not noticed its own product description is about a different molecule has not read its own product description.

The evidence, which is the same for every provider we rank

Setting aside how Strut describes it, the underlying position on this site does not move for a paid partner. No rigorous human trial shows that injected NAD+ improves cognition, focus or energy. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo¹; a second randomised trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit either²; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all³.

The full picture is in our review of what the NAD+ evidence supports and what it does not. The compounded preparation Strut dispenses is also not an FDA-approved product, and a compounded drug is not a generic equivalent of an approved one⁴ — which is worth holding beside the fact that its own page describes the molecule incorrectly.

Who it is for

If you want an injection, a published dose, a state list that reconciles and a certification that resolves, Strut delivers all four, and at $149 it is toward the cheaper end of what we rank. If you are the kind of buyer who wants to cancel a subscription and pay per order, the price you would pay is not published, and on the one line where Strut shows both numbers the gap is 63%.

And if you are choosing partly on whether a company understands the thing it sells, the NAD+ page is the evidence you have. It says the product is a peptide that signals your pituitary gland. We wrote a whole piece on how NAD+ is marketed against how nootropics are marketed, and the pattern is the same one: the more confidently a page explains the mechanism, the less often the explanation is checked.

The bottom line

Strut Health sells a compounded 500 mg NAD+ injection from $149 on auto-refill, publishes the dose, publishes a state list that agrees with itself, and carries a LegitScript certification that resolves to a real record. It also names no pharmacy, has not updated its refund policy since 2021, does not publish a one-off price for the product, and carries a live FDA warning letter — addressed to Strut Health, LLC dba Strut, issued February 2026, not closed out — which it does not mention anywhere on its own site. And the page selling you NAD+ tells you NAD+ is a peptide that signals your pituitary gland, which is a description of something else.